This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Vosaroxin
- DrugBank Accession Number
- DB11999
- Background
Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Vosaroxin (DB11999)
- Weight
- Average: 401.44
Monoisotopic: 401.115775286 - Chemical Formula
- C18H19N5O4S
- Synonyms
- Voreloxin
- Vosaroxin
- External IDs
- AG-7352
- SNS-595
- SPC-595
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Vosaroxin is combined with Cinchocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- L01XX53 — Vosaroxin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as naphthyridine carboxylic acids and derivatives. These are compounds containing a naphthyridine moiety, where one of the ring atoms bears a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazanaphthalenes
- Sub Class
- Naphthyridines
- Direct Parent
- Naphthyridine carboxylic acids and derivatives
- Alternative Parents
- Pyridinecarboxylic acids / Dialkylarylamines / Aminopyridines and derivatives / Imidolactams / Vinylogous amides / Thiazoles / Pyrrolidines / Heteroaromatic compounds / Amino acids / Dialkylamines show 5 more
- Substituents
- Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aromatic heteropolycyclic compound / Azacycle / Azole / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether show 19 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- K6A90IIZ19
- CAS number
- 175414-77-4
- InChI Key
- XZAFZXJXZHRNAQ-STQMWFEESA-N
- InChI
- InChI=1S/C18H19N5O4S/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26)/t12-,13-/m0/s1
- IUPAC Name
- 7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
- SMILES
- CN[C@H]1CN(C[C@@H]1OC)C1=CC=C2C(=O)C(=CN(C3=NC=CS3)C2=N1)C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 9952884
- PubChem Substance
- 347828318
- ChemSpider
- 8128494
- ChEMBL
- CHEMBL68117
- ZINC
- ZINC000026186622
- Wikipedia
- Vosaroxin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Acute Myeloid Leukemia 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With Multilineage Dysplasia / Granulocytic Sarcoma / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Myelodysplastic Syndrome / Treatment-Related Acute Myeloid Leukemia 1 2 Completed Treatment Acute Disease / Acute Myeloid Leukemia / Leukemias / Myelodysplastic Syndrome / Nonlymphocytic Leukemia 1 2 Completed Treatment Acute Myeloid Leukemia / Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) 1 2 Completed Treatment Epithelial Ovarian Cancer 1 2 Completed Treatment Non-Small Cell Lung Carcinoma 1 2 Completed Treatment Small Cell Carcinoma / Small Cell Lung Cancer (SCLC) 1 2, 3 Recruiting Treatment Acute Myeloid Leukemia 1 2, 3 Unknown Status Treatment Acute Myeloid Leukemia / Myelodysplastic Syndrome 1 1 Active Not Recruiting Treatment Myelodysplastic Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.128 mg/mL ALOGPS logP -0.49 ALOGPS logP -0.42 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 5.06 Chemaxon pKa (Strongest Basic) 8.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 107.89 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 103 m3·mol-1 Chemaxon Polarizability 41.3 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:09 / Updated at January 14, 2023 19:03